Zhang Ying, Jiao Jing, Yang Pengyuan, Lu Haojie
Key Laboratory of Glycoconjuates Research Ministry of Public Health and Institutes of Biomedical Sciences, Fudan University Shanghai, 200032, China.
Department of Chemistry, Fudan University, Shanghai 200433, China.
Clin Proteomics. 2014 May 5;11(1):18. doi: 10.1186/1559-0275-11-18. eCollection 2014.
Glycosylation is estimated to be found in over 50% of human proteins. Aberrant protein glycosylation and alteration of glycans are closely related to many diseases. More than half of the cancer biomarkers are glycosylated-proteins, and specific glycoforms of glycosylated-proteins may serve as biomarkers for either the early detection of disease or the evaluation of therapeutic efficacy for treatment of diseases. Glycoproteomics, therefore, becomes an emerging field that can make unique contributions to the discovery of biomarkers of cancers. The recent advances in mass spectrometry (MS)-based glycoproteomics, which can analyze thousands of glycosylated-proteins in a single experiment, have shown great promise for this purpose. Herein, we described the MS-based strategies that are available for glycoproteomics, and discussed the sensitivity and high throughput in both qualitative and quantitative manners. The discovery of glycosylated-proteins as biomarkers in some representative diseases by employing glycoproteomics was also summarized.
据估计，超过50%的人类蛋白质存在糖基化现象。蛋白质糖基化异常和聚糖改变与许多疾病密切相关。超过一半的癌症生物标志物是糖基化蛋白，糖基化蛋白的特定糖型可作为疾病早期检测或疾病治疗疗效评估的生物标志物。因此，糖蛋白质组学成为一个新兴领域，可为癌症生物标志物的发现做出独特贡献。基于质谱（MS）的糖蛋白质组学的最新进展能够在一次实验中分析数千种糖基化蛋白，为此展现出了巨大潜力。在此，我们描述了可用于糖蛋白质组学的基于质谱的策略，并从定性和定量方面讨论了其灵敏度和高通量。还总结了通过糖蛋白质组学在一些代表性疾病中发现糖基化蛋白作为生物标志物的情况。
